Home » Stocks » Altimmune

Altimmune, Inc. (ALT)

Stock Price: $11.05 USD -0.34 (-2.99%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $11.10 +0.05 (0.45%) Oct 21, 6:32 PM

Stock Price Chart

Key Info

Market Cap 363.68M
Revenue (ttm) 4.15M
Net Income (ttm) -35.69M
Shares Out 32.91M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $11.05
Previous Close $11.39
Change ($) -0.34
Change (%) -2.99%
Day's Open 11.25
Day's Range 10.95 - 11.55
Day's Volume 826,109
52-Week Range 1.51 - 35.10

More Stats

Market Cap 363.68M
Enterprise Value 284.05M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.91M
Float 30.83M
EPS (basic) -2.19
EPS (diluted) -2.27
FCF / Share -0.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.08M
Short Ratio 1.33
Short % of Float 6.76%
Beta 1.51
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 87.55
PB Ratio 5.37
Revenue 4.15M
Operating Income -41.31M
Net Income -35.69M
Free Cash Flow -16.00M
Net Cash 79.63M
Net Cash / Share 2.42
Gross Margin -271.64%
Operating Margin -994.44%
Profit Margin -859.10%
FCF Margin -385.15%
ROA -19.75%
ROE -52.58%
ROIC -156.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$49.00*
(343.44% upside)
Low
31.0
Current: $11.05
High
80.0
Target: 49.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue5.8010.3310.743.2410.6410.1917.9125.1824.2720.99
Revenue Growth-43.85%-3.79%231.82%-69.59%4.42%-43.11%-28.85%3.75%15.59%-
Gross Profit5.8010.3310.743.2410.6410.1917.9125.1824.2720.99
Operating Income-21.46-42.83-52.05-11.09-3.40-10.19-10.84-6.27-11.73-23.55
Net Income-20.52-39.17-46.43-11.09-3.44-9.96-11.72-4.92-3.80-34.85
Shares Outstanding13.122.800.430.230.210.190.170.160.160.11
Earnings Per Share-1.60-15.16-118.91-49.81-15.00-51.01-69.01-30.00-24.00-324.03
Operating Cash Flow-9.60-9.39-20.21-6.35-3.22-8.47-7.17-2.32-7.81-14.86
Capital Expenditures-0.03-1.00-0.16-0.22-0.08-0.08-0.080.07-0.07-0.37
Free Cash Flow-9.63-10.39-20.37-6.57-3.29-8.56-7.25-2.26-7.88-15.24
Cash & Equivalents37.2734.3512.302.8815.5718.6410.4812.7011.3411.89
Total Debt-0.070.050.46-0.752.823.781.898.36
Net Cash / Debt37.2734.2812.252.4215.5717.907.668.929.453.52
Assets54.0654.7563.0338.4019.8621.9817.1422.7422.8027.20
Liabilities8.546.4414.356.193.213.709.8011.076.9514.99
Book Value45.5248.3139.4032.2116.6518.277.3411.6715.8512.21
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Altimmune, Inc.
Country United States
Employees 25
CEO Vipin K. Garg

Stock Information

Ticker Symbol ALT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALT

Description

Altimmune, a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.